UPC_CFI_624/2025
ANALYTE SENSOR METHODS
Abbott Diabetes Care obtained a preliminary injunction from The Hague Local Division against Sinocare and A. Menarini Diagnostics prohibiting the GlucoMen iCan CGM system across all UPC territories for infringement of EP 4 344 633 (FreeStyle Libre analyte sensor technology). The court also ordered delivery-up of infringing products and disclosure of distribution channels, but rejected Abbott's request for a customs-goods declaration under EU Regulation 608/2013 as unavailable in PI proceedings, and limited the information order to distribution data rather than financial figures.
GlucoMen iCan infringes EP 4 344 633 covering continuous glucose monitoring sensor technology
KlägerRechtsgrundlage: Art. 62 UPCA; R. 211 RoPHinweis: The Hague Local Division found infringement sufficiently demonstrated for PI purposes and granted the injunction across all UPC member states.
Defendants should not be ordered to comply jointly and severally as independent companies
BeklagterHinweis: Court agreed that Sinocare and Menarini are independent companies and did not impose joint and several liability for the substantive injunction obligations.
Declaration that GlucoMen iCan is 'goods suspected of infringing an IP right' under EU Regulation 608/2013 should be granted as a provisional measure
KlägerRechtsgrundlage: Art. 2(7)(a) of Regulation (EU) No 608/2013Begründung: Court held that such a declaration is not available as a provisional measure regardless of the merits.
Information order should include price, sales numbers, and cost data
KlägerRechtsgrundlage: R. 211 RoPBegründung: Court found that financial data is only relevant for damages calculation which is premature at the PI stage; the information order was limited to distribution channels and product origins.
Information disclosure should be subject to confidentiality
BeklagterBegründung: Court rejected confidentiality request given the limited scope of the ordered information disclosure.
Weitere Fälle zu diesem Grundsatz ansehen.